James M Donahue

Dr. James M Donahue

School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Mina ZareMina Zare
Mina Zare
RPRakesh Pemmada
Rakesh Pemmada
MMMaya Madhavan
Maya Madhavan
ASAswathy Shailaja
Aswathy Shailaja
Seeram RamakrishnaSeeram Ramakrishna
Seeram Ramakrishna
Vinoy ThomasVinoy Thomas
Vinoy Thomas
Globally, cancer is amongst the most deadly diseases due to the low efficiency of the conventional and obsolete chemotherapeutic methodologies and their many downsides. The poor aqueous solubility of most anticancer medications and their low biocompatibility make them ineligible candidates for the design of delivery systems. A significant drawback associated with chemotherapy is that there are no advanced solutions to multidrug resistance, which poses a major obstacle in cancer management. Since RNA interference (RNAi) can repress the expression of genes, it is viewed as a novel tool for advanced drug delivery. this is being explored as a promising drug targeting strategy for the treatment of multiple diseases, including cancer. However, there are many obstructions that hinder the clinical uses of siRNA drugs due to their low permeation into cells, off-target impacts, and possible unwanted immune responses under physiological circumstances. Thus, in this article, we review the design measures for siRNA conveyance frameworks and potential siRNA and miRNA drug delivery systems for malignant growth treatment, including the use of liposomes, dendrimers, and micelle-based nanovectors and functional polymer–drug delivery systems. This article sums up the advancements and challenges in the use of nanocarriers for siRNA delivery and remarkably centers around the most critical modification strategies for nanocarriers to build multifunctional siRNA and miRNA delivery vectors. In short, we hope this review will throw light on the dark areas of RNA interference, which will further open novel research arenas in the development of RNAi drugs for cancer.

31 December 2020 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
PPPornima Phatak
Pornima Phatak
MNMichael Noe
Michael Noe
KAKaushal Asrani
Kaushal Asrani
IGIngrid E Graves
Ingrid E Graves
BGBruce D. Greenwald
Bruce D. Greenwald
JDJames M Donahue
James M Donahue

5 December 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PPPornima Phatak
Pornima Phatak
WBWhitney M. Burrows
Whitney M. Burrows
TCTimothy Michael Creed
Timothy Michael Creed
MYMariam Youssef
Mariam Youssef
GLGoo Lee
Goo Lee
JDJames M Donahue
James M Donahue
Background: MicroRNA (miR)-214-3p is emerging as an important tumor suppressor in esophageal cancer. In this study, we examined the interaction between miR-214-3p and RAB14, a membrane trafficking protein shown to exert oncogenic functions in other malignancies, in esophageal cancer cells. Methods: Studies were performed in a human esophageal epithelial cell line and a panel of esophageal cancer cell lines, as well in human specimens. MiR-214-3p expression was measured by digital PCR. Biotinylated RNA pull-down and luciferase reporter assays assessed binding. The xCELLigence RTCA system measured cell migration and invasion in real time. A lentiviral expression vector was used to create an esophageal cancer cell line stably expressing miR-214-3p. Results: MiR-214-3p expression was decreased in esophageal cancer cell lines and human specimens compared to non-malignant controls. RAB14 mRNA stability and protein expression were decreased following miR-214-3p overexpression. Binding between miR-214-3p and RAB14 mRNA was observed. Either forced expression of miR-214-3p or RAB14 silencing led to a marked decrease in cellular migration and invasion. Esophageal cancer cells stably expressing miR-214-3p demonstrated decreased growth in a subcutaneous murine model. Conclusions: These results further support the tumor-suppressive role of miR-214-3p in esophageal cancer cells by demonstrating its ability to regulate RAB14 expression.

30 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
PPPornima Phatak
Pornima Phatak
MTMohan E Tulapurkar
Mohan E Tulapurkar
WBWhitney M. Burrows
Whitney M. Burrows
JDJames M Donahue
James M Donahue
MicroRNA (miR)-199a-5p has been shown to function as a tumor suppressor in some malignancies but its role in esophageal cancer is poorly understood. To further explore its role in esophageal cancer, we sought to investigate the interaction between miR-199a-5p and Jun-B, an important component of the AP1 transcription factor, which contains a potential binding site for miR-199a-5p in its mRNA. We found that levels of miR-199a-5p are reduced in both human esophageal cancer specimens and in multiple esophageal cancer cell lines compared to esophageal epithelial cells. Jun-B expression is correspondingly elevated in these tumor specimens and in several cell lines compared to esophageal epithelial cells. Jun-B mRNA expression and stability, as well as protein expression, are markedly decreased following miR-199a-5p overexpression. A direct interaction between miR-199a-5p and Jun-B mRNA was confirmed by a biotinylated RNA-pull down assay and luciferase reporter constructs. Either forced expression of miR-199a-5p or Jun-B silencing led to a significant decrease in cellular proliferation as well as in AP-1 promoter activity. Our results provide evidence that miR-199a-5p functions as a tumor suppressor in esophageal cancer cells by regulating cellular proliferation, partially through repression of Jun B.


1 January 2018 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
RKRajat Kumar
Rajat Kumar
JDJames M Donahue
James M Donahue
Editorial for economic impact of an enhanced recovery pathway for lung resection